

如何獲得Colour測試？ How Do I Get The Color Test?



1. 您的醫生訂購測試
Your doctor orders the test

與您的醫生討論遺傳性癌症基因檢測是否適合您。遺傳諮詢可應要求提供。

Your doctor orders the test Discuss with your doctor whether the hereditary cancer genetic test is right for you. genetic counselling is available upon request



2. Provide a saliva sample
提供唾液樣本

你的唾液樣本將被收集在管中。當您的樣品到達我們的實驗室時，您的基因將進行測序和分析

Your saliva sample will be collected in the tube. When your sample arrives in our laboratory, your genes will be sequenced and analyzed



3. Results available in 3-4 weeks,
on average
平均可在3-4週內獲得結果

Receive your results from your doctor.
從您的醫生處接收您的結果。



4. Create a plan with your
provider
與您的供應商一起制定計劃

您的結果可以幫助您和您的醫生製定個性化的篩查和預防計劃。

Your results can help you and your doctor create a personalized screening and prevention plan.

Color分析包括BRCA1和BRCA2在內的30個基因 Color analyzes 30 genes including BRCA1 & BRCA2

以幫助女性和男性了解自己患上最常見的遺傳性癌症，包括乳腺癌，卵巢癌，結直腸癌和胰腺癌的風險

to help women and men understand their risk for the most common hereditary cancers, including breast, ovarian, colorectal, and pancreatic cancer.



About Us

Clearbridge Medical Group is set apart by direct access to Clearbridge labs and the breakthroughs at our MedTech Innovation Suites. Clearbridge Medical Group continues to establish our leadership in the competitive healthcare sector and are set to open medical clinics/centres across 11 countries in Asia, including Singapore, Malaysia, the Philippines, Indonesia, India, Hong Kong and China.

Clearbridge Medical Group is a subsidiary of Clearbridge Health Limited, an integrated healthcare group with a focus on the delivery of precision medicine with businesses comprising of laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies.

Listed on The Catalist Board of the SGX-ST and incorporated in January 2010, Clearbridge Health Limited continues to provide ever more effective ways to detect cancer, critical illness, and other lifestyle diseases sweeping the world today.

Information is correct as at 05 March 2018



了解您最常見的 遺傳性癌症 的遺傳風險

Learn about your genetic risk
for the most common hereditary cancers



37 Jalan Pemimpin #08-05
Mapex Singapore 577177
t +65 6251 0136 f +65 6251 0132
clearbridgemedical.com

*E&OE
March 2018*

In partnership with
color

為什麼進行基因測試？Why Get Genetic Testing?

個人化篩查和預防 Personalized screening and prevention


10-15%的大多數癌症是由於遺傳基因突變導致的。知道自己有否會增加你患癌風險的基因突變，使你和你的醫療保健提供者能夠訂立一個個人化的計劃，以預防或在更早或可治療的階段檢測乳腺癌，卵巢癌，結腸直腸癌，胰腺癌。

10-15% of most cancers are due to inherited genetic mutations.1-3 Knowing you have a mutation that increases your risk allows you and your healthcare provider to create a personalized plan designed to prevent or detect cancers like breast, ovarian, colorectal, and pancreatic at an earlier or more treatable stage.


親屬也可以受惠
Relatives may benefit too

知道你有遺傳突變可能是一個與你的親屬分享的重要信息。例如，如果一個男性帶有BRCA1突變，他的每個孩子都有50%的機會帶有相同的突變。

Knowing you have a genetic mutation may be important information to share with your relatives. For example, if a man carries a mutation in BRCA1, each of his children has a 50% chance of carrying the same mutation.



色彩體驗 The Color Experience



綜合分析30個基因
Comprehensive analysis of 30 genes

Color分析30個與最常見的遺傳性癌症相關的基因：包括乳腺癌，結腸直腸癌，黑素瘤，胰腺癌，前列腺癌，卵巢癌，胃癌和子宮癌。

Color analyzes 30 genes associated with the most common hereditary cancers: breast, colorectal, melanoma, pancreatic, prostate*, ovarian, stomach, and uterine.

可根據要求提供遺傳諮詢
Genetic counseling is available upon request

Color擁有一支我們的專業資格認證的遺傳學諮詢師團隊，以回答您對您的結果提出的任何問題。目前，Color的遺傳學諮詢只能以英語進行。

Colour offers you and your healthcare provider access to our team of board-certified genetic counselors to answer any questions you may have about your results. Currently, genetic counseling from Color is only available in English.

富信息性的結果
Informative results

清晰地顯示任何有可能增加風險的突變（包括突變細節和對癌症風險的影響）

Clear, thorough communication of the presence of any risk-increasing mutations, including mutation details and the impact on cancer risks

有關突變狀態如何影響親屬的詳細信息

Detailed information on how your mutation status might affect relatives

由專家建議的篩查方針，與您的醫療保健提供者進行討論

Screening guidelines created by experts to discuss with your healthcare provider

回答常見問題

Answers to common questions

請注意，遺傳性前列腺癌相關基因的研究和篩選指南仍處於早期階段。如果與您的結果相關的任何信息發生變化，它就是Color服務的一部分，可以讓您隨時更新。

Please note that research and screening guidelines for genes associated with hereditary prostate cancer are still in their early stages. It is part of the Color service to keep you updated if any information related to your results changes.

關於Color About Color

您的隱私是我們的首要任務
Your privacy is our priority

We take your privacy very seriously and only collect the information that is needed to provide you with a high-quality experience. Color voluntarily complies with the Health Insurance Portability and Accountability Act (HIPAA) regarding protected health information. 我們非常重視您的隱私，我們只收集所需的信息，為您提供高質量的體驗。Color自願遵守有關受保護健康信息的健康保險可攜性和責任法案（HIPAA）。

臨床級基因檢測
Clinical-grade genetic testing

Color實驗室已獲得美國病理學家協會（CAP）的認可，並擁有臨床實驗室改進修正案（CLIA）認證。Color Test在多項驗證研究中顯示出> 99%的準確性

Color's laboratory has been accredited by the College of American Pathologists (CAP) and has Clinical Laboratory Improvement Amendments (CLIA) certification. The Color Test showed >99% accuracy in multiple validation studies

Color涵蓋與最常見的遺傳性癌症相關的基因
Color covers genes associated with the most common hereditary cancers

APC	CDH1	MLH1	POLE
ATM	CDK4	MSH2	PTEN
BAP1	CDKN2A (p14ARF)	MSH6	RAD51C
BARD1	CDKN2A (p16INK4a)	MUTYH	RAD51D
BMPR1A	CHEK2	NBN	SMAD4
BRCA1	EPCAM	PALB2	STK11
BRCA2	GREM1	PMS2	TP53
BRIPI	MITF	POLD1	

References

- ¹ Tung N et al. Cancer 121(1), 2015.
- ² Pal T et al. Cancer 104(12), 2005.
- ³ Risch HA et al. The American Journal of Human Genetics 68(3), 2001.
- ⁴ SEER Stat Fact Sheets: Breast Cancer. National Cancer Institute. Accessed January 2016.
- ⁵ King MC et al. Science 302(5645), 2003.
- ⁶ Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastro. 2010 Jun; 138(6):2044-58.
- ⁷ Burt RW, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastro. 2004 Aug; 127(2):444-51.